



Standing Way Eaglestone Milton Keynes MK6 5LD 01908 660033 www.mkuh.nhs.uk

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 09/10/2023. I am pleased to confirm the following:

We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality, Vyepti, Vydura & Aquipta) for migraine. Could you please answer the following:

Does the trust commission/fund Botox treatment for migraine (Y/N)? N, we provide botox treatment for migraine, but this is commissioned and funded by the patient's ICB.

Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)? N, we provide anti-CGRP treatments for migraine, but this is commissioned and funded by the patient's ICB.

Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments? Yes, we actively provide these treatments for patients.

In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust. The majority of the patients receiving these treatments will be funded by Bedford, Luton and Milton Keynes (BLMK) Integrated Care Board.

How many patients have been treated with the following drugs in the past 4 months:

•	Atogepant (Aquipta) – any disease	0 patients
•	Erenumab (Aimovig) - any disease	23 patients
•	Eptinezumab (Vyepti) – any disease	0 patients
•	Fremanezumab (Ajovy) - any disease	1 patient
•	Galcanezumab (Emgality) - any disease	0 patients
•	Rimegepant (Vydura) – any disease	0 patients

• Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY – We are not able to link drugs to an indication for use.

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be





Chief Executive: Joe Harrison

Chair: Alison Davis

subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.